Nutriband Selects Global Brand Name for Abuse-Deterrent Fentanyl Patch Technology

Nutriband Inc. (NASDAQ: NTRB) announced it has selected a proposed worldwide brand name for its abuse-deterrent fentanyl transdermal system, with plans to submit the name and product labeling to the FDA and international regulators as well as file for trademark protection. The company said the product, developed using its AVERSA™ technology, could become the first abuse-deterrent fentanyl patch designed to reduce misuse and accidental exposure, targeting a potential peak annual U.S. market of $80 million to $200 million while addressing broader global pain management needs.

The company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products, with its lead product under development being an abuse-deterrent fentanyl patch incorporating its AVERSA™ abuse-deterrent technology. This technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company's website is https://www.nutriband.com, though any material contained in or derived from the company's websites is not part of the official press release.

The announcement was made through BioMedWire, a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release services, social media distribution, and tailored corporate communications solutions. More information about BioMedWire is available at https://www.BioMedWire.com, with full terms of use and disclaimers applicable to all content provided by BMW available at https://www.BioMedWire.com/Disclaimer.

The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. The full press release can be viewed at https://ibn.fm/QBBSF. This development represents a significant step in addressing the ongoing opioid crisis through technological innovation in pain management delivery systems. The abuse-deterrent properties of the AVERSA™ technology could potentially reduce the public health impact of fentanyl misuse while maintaining therapeutic benefits for legitimate pain patients.

Regulatory approval processes for both the product name and the underlying technology will be critical next steps for Nutriband as it seeks to bring this innovation to market. The company's focus on both domestic and international regulatory submissions indicates a strategic approach to global commercialization. The estimated market size of $80 million to $200 million annually in the United States alone underscores the significant commercial potential of abuse-deterrent opioid formulations, particularly as healthcare systems and regulators increasingly prioritize solutions to combat prescription drug abuse.